Kura Oncology at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Kura Oncology exhibits at Booth 2229 at ASH 2026 in New Orleans. Kura Oncology supports symposia on acute myeloid leukemia, with a focus on precision treatment and second-opinion review of patient cases. The most specific looks at how menin inhibitors fit into precision care for the disease.
| Organization | ASH 2026 Attendance |
|---|---|
Kura Oncology San Diego, CA | |
Precision oncology company developing ziftomenib, a menin inhibitor for acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements, and other targeted cancer drugs. | Booth Exhibiting at Booth 2229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 3:00pm–6:00pm Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome. |
Instantly find 20 buyers from Kura Oncology
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction